RESEARCH PAPER
Ventilator-associated pneumonia (VAP) caused by Acinetobacter baumannii in view of the microbial properties of the ESKAPE group in neighbouring countries – Poland and Ukraine
 
More details
Hide details
1
Laboratory of Microbiology, Masovian Specialistic Hospital in Radom, Poland
2
Pope John Paul II State School of Higher Education in Biała Podlaska, Poland
3
I. Horbachevsky Ternopil State Medical University, Ukraine
4
Ternopil Medical University Hospital, Ternopil, Ukraine
CORRESPONDING AUTHOR
Aneta Grochowalska   

Laboratory of Microbiology, Masovian Specialistic Hospital in Radom, Poland, Aleksandrowicza 5, 26-617 Radom, Poland
 
J Pre Clin Clin Res. 2017;11(2):111–115
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The increase in the clinical threat of ESKAPE pathogens is associated with high virulence and the presence of numerous mechanisms of antimicrobial resistance. The above characteristics of pathogens affect therapeutic failures as well as cause prolongation and increase of the cost of its treatment.

Objective:
The aim of this study was to evaluate and analyze Acinetobacter baumannii strains in relation to the remaining bacteria from the ESKAPE group that induced pneumonia in mechanically ventilated patients in two neighboring countries.

Materials and method:
The study was retrospective. 335 clinical materials were analyzed, mainly bronchoalveolar lavage gained for microbiological screen. The analyzed patients were in intensive care units (ICU) in selected hospitals in 2013 – 2015, in Poland (154 patients) and in Ukraine (181 patients).

Results:
In the analysis of etiological agents of VAP caused by ESKAPE strains, Gram negative bacteria were predominant in both countries although particular species occurred at different frequencies in Poland and Ukraine. Multi-resistant strains of Acinetobacter baumannii were more frequently cultured from patients in Poland (26.9%) compared to those from Ukraine (14.6%).

 
REFERENCES (22)
1.
Renner LD, Zan J, Hu LI, Martinez M, Resto PJ, Siegel AC, Torres C, Hall SB, Slezak TR, Nguyen TH, Weibel DB. Detection of ESKAPE Bacterial Pathogens at the Point of Care Using Isothermal DNA-Based Assays in a Portable Degas-Actuated Microfluidic Diagnostic Assay Platform. Appl Environ Microbiol. 2017; 83(4).
 
2.
Hubick S, Jayaraman A, McKeen A, Reid S, Alcorn J, Stavrinides J, Sterenberg BT. A potent synthetic inorganic antibiotic with activity against drug-resistant pathogens. Sci Rep. 2017; 7: 41999.
 
3.
Meeker DG, Jenkins SV, Miller EK, Beenken KE, Loughran AJ, Powless, Muldoon TJ, Galanzha EI, Zharov VP, Smeltzer MS, Chen J. Synergistic Photothermal and Antibiotic Killing of Biofilm-Associated Staphylococcus aureus Using Targeted Antibiotic-Loaded Gold Nanoconstructs. ACS Infect Dis. 2016; 2(4): 241–250.
 
4.
Bales PM, Renke EM, May SL, Shen Y, Nelson DC. Purification and Characterization of Biofilm-Associated EPS Exopolysaccharides from ESKAPE Organisms and Other Pathogens. PLoS One. 2013; 8(6).
 
5.
Behroozian S, Svensson SL, Davies J. Kisameet Clay Exhibits Potent Antibacterial Activity against the ESKAPE Pathogens. MBio. 2016; 7(1).
 
6.
Bonnin RA, Poirel L, Nordmann P. New Delhi metallo-β-lactamase-producing Acinetobacter baumannii: a novel paradigm for spreading antibiotic resistance genes. Future Microbiol. 2014; 9(1): 33–41.
 
7.
Lob SH, Hoban DJ, Sahm DF, Badal RE. Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii. Int J Antimicrob Agents. 2016; 47(4): 317–23.
 
8.
Santajit S, Indrawattana N. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. Biomed Res Int. 2016; 2016: 2475067.
 
9.
Bionda N, Fleeman RM, de la Fuente-Nunez C, Rodriguez MC, Reffuveille F, Shaw L, Pastar I, Davis SC, Hancock RE, Cudic P. Identification of novel cyclic lipopeptides from a positional scanning combinatorial library with enhanced antibacterial and antibiofilm activities. Eur J Med Chem. 2016; 108: 354–63.
 
10.
Hsu LY, Apisarnthanarak A, Khan E, Suwantarat N, Ghafur A, Tambyah PA. Carbapenem-Resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia. Clin Microbiol Rev. 2017; 30(1): 1–22.
 
11.
Bassetti M, Luyt CE, Nicolau DP, Pugin J. Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient. Ann Intensive Care. 2016; 6(1): 35.
 
12.
Hryniewicz W, Ozorowski T. Recommendations for the diagnosis, antibiotic treatment and prevention of infections in hospitals. 2015. http://antybiotyki.edu.pl (in Polish).
 
13.
Masterton RG, Galloway A, French G, et al. Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the Working Party on Hospital-Acquired Pneumonia of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother. 2008; 62: 5–34.
 
14.
Rotstein C, Evans G, Born A, et al. Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. Can J Infec Dis Med Microbiol. 2008; 19: 19–53.
 
15.
American Thoracic Society, Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005; 171: 388–416.
 
16.
Penwell WF, Shapiro AB, Giacobbe RA, Gu RF, Gao N, Thresher J, McLaughlin RE, Huband MD, DeJonge BL, Ehmann DE, Miller AA. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob Agents Chemother. 2015; 59(3): 1680–9.
 
17.
Fishbain J, Peleg AY. Treatment of Acinetobacter Infections. Clin Infect Dis (2010) 51(1): 79–84.
 
18.
Cardoso T, Ribeiro O, Aragao IC, Costa-Pereira A, Sarmento AE. Additional risk factors for infection by multidrug-resistant pathogens in healthcare-associated infection: a large cohort study. BMC Infect Dis. 2012; 12: 375.
 
19.
De Rosa FG, Corcione S, Pagani N, Di Perri G. From ESKAPE to ESCAPE, from KPC to CCC. Clin Infect Dis. 2015; 60(8): 1289–90.
 
20.
Mogyorodi B, Dunai E, Gal J, Ivanyi Z. Ventilator-associated pneumonia and the importance of education of ICU nurses on prevention – Preliminary results. Interv Med Appl Sci. 2016; 8(4): 147–151.
 
21.
Chung H, Lieberman TD, Vargas SO, Flett KB, McAdam A, Priebe GP, Kishony R. Global and local selection acting on the pathogen Stenotrophomonas maltophilia in the human lung. Nat Commun. 2017; 8: 14078.
 
22.
Ebara H, Hagiya H, Haruki Y, Kondo E, Otsuka F. Clinical Characteristics of Stenotrophomonas maltophilia Bacteremia: A Regional Report and a Review of a Japanese Case Series. Intern Med. 2017; 56(2): 137–142.
 
eISSN:1898-7516
ISSN:1898-2395